Overview

A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)

Status:
Active, not recruiting

Trial end date:
2022-08-04

Target enrollment:

Participant gender:

Summary

The main objective of this study is to evaluate the safety and efficacy of elsubrutinib, upadacitinib, and ABBV-599 vs placebo for the treatment of signs and symptoms of Systemic Lupus Erythematosus (SLE) in participants with moderately to severely active SLE and to define doses for further development.

Phase:

Phase 2

Details

Lead Sponsor:

AbbVie

Treatments:

Upadacitinib